Wyss

EnPlusOne Biosciences to Address Advances in the Enzymatic Synthesis of RNA at the 11th Annual Oligo Networking Conference

Retrieved on: 
Monday, March 4, 2024

EnPlusOne Biosciences, Inc. , a biotechnology company harnessing the power of enzymes to deliver sustainable RNA at scale, today announced that Dan Ahlstedt, COO, will be presenting the company’s ezRNA™ platform at the 11th Annual Oligo Networking Conference at GSK’s Stevenage (UK) campus on March 5, 2024.

Key Points: 
  • EnPlusOne Biosciences, Inc. , a biotechnology company harnessing the power of enzymes to deliver sustainable RNA at scale, today announced that Dan Ahlstedt, COO, will be presenting the company’s ezRNA™ platform at the 11th Annual Oligo Networking Conference at GSK’s Stevenage (UK) campus on March 5, 2024.
  • The two-day event will feature speakers from companies across life sciences discussing opportunities and challenges associated with the use of oligonucleotides in R&D and manufacturing by biopharmaceutical companies.
  • Mr. Ahlstedt’s presentation will highlight recent technical developments, and upcoming milestones, on the company’s proprietary enzymatic RNA oligonucleotide synthesis technology, as part of the Innovation in Manufacturing session at the event.
  • This community, from the beginning, has been supportive of our mission to deliver sustainable RNA at scale.

The Wyss Foundation Provides $5 Million in Funding for Children's Hospital of Philadelphia's Wyss/Campbell Center for Thoracic Insufficiency Syndrome

Retrieved on: 
Thursday, February 22, 2024

PHILADELPHIA, Feb. 22, 2024 /PRNewswire/ -- Children's Hospital of Philadelphia (CHOP) is thrilled to announce a gift of $5 million from the Wyss Foundation to support innovations that improve the lives of patients with thoracic insufficiency syndrome (TIS). An initial gift from Hansjörg Wyss, philanthropist and chairman of the Wyss Foundation, was made to CHOP in 2019 and honored the legacy of the late Dr. Robert Campbell, a world-renowned CHOP pediatric orthopaedic surgeon. Now, additional funding has renamed and established the Wyss/Campbell Center for Thoracic Insufficiency Syndrome, one of CHOP's frontier programs, a trailblazing group of initiatives pioneering new advances in children's health. 

Key Points: 
  • Now, additional funding has renamed and established the Wyss/Campbell Center for Thoracic Insufficiency Syndrome , one of CHOP's frontier programs, a trailblazing group of initiatives pioneering new advances in children's health.
  • The $5 million gift will ensure the Center, its clinical team, researchers and patients have the resources needed to thrive by amplifying studies, tools and education.
  • The Center will be named Wyss/Campbell Center for Thoracic Insufficiency Syndrome in perpetuity.
  • The Wyss Foundation is honored to support the team working to improve the quality of life for children living with TIS," said Molly McUsic, President of the Wyss Foundation.

EnPlusOne Biosciences to Attend and Present Poster at OTS Annual Meeting

Retrieved on: 
Friday, October 20, 2023

The company, which is a bronze level sponsor of the annual meeting, will also be delivering a poster presentation that highlights recent technical developments on its propriety enzymatic RNA oligonucleotide synthesis technology.

Key Points: 
  • The company, which is a bronze level sponsor of the annual meeting, will also be delivering a poster presentation that highlights recent technical developments on its propriety enzymatic RNA oligonucleotide synthesis technology.
  • The poster presentation is entitled “A Platform for Controlled Enzymatic Synthesis of RNA Oligonucleotides“ and will be delivered by Dominic Rainone, an Associate Scientist at EnPlusOne Biosciences, during Poster Session 1, which begins at 17:00 on October 23rd.
  • Additional technical data from this poster can also be found in EnPlusOne’s recent manuscript pre-print available online.
  • Likewise, we’ve been very strong supporters of OTS and its mission to bring the field of oligonucleotides to its full therapeutic potential.

Wyss Center Appoints Dr. Craig Cook as New Head of Business Development and Licensing

Retrieved on: 
Monday, July 10, 2023

The Wyss Center, a leading non-profit research center dedicated to innovating and accelerating technologies and therapies for neurological and mental health disorders, is pleased to announce the appointment of Craig Cook, MD, MBA, to the leadership team as Head of Business Development and Licensing.

Key Points: 
  • The Wyss Center, a leading non-profit research center dedicated to innovating and accelerating technologies and therapies for neurological and mental health disorders, is pleased to announce the appointment of Craig Cook, MD, MBA, to the leadership team as Head of Business Development and Licensing.
  • Dr. Cook brings more than 25 years of impressive executive leadership and entrepreneurial expertise in the fields of biotech, medtech and clinical medicine.
  • View the full release here: https://www.businesswire.com/news/home/20230710043091/en/
    “The addition of Craig to the Wyss Center team comes at a pivotal time,” said Erwin Bottinger, MD, CEO of the Wyss Center, “Craig brings a wealth of experience in translating medical technologies and therapies into clinical impact.
  • Dr. Cook's extensive track record complements the Wyss Center's commitment to neurological and mental health, strengthening its science and technology portfolio.

Harvard’s Wyss Institute and Collaborative Fund cofound research lab to fund technology to combat climate change

Retrieved on: 
Tuesday, May 23, 2023

Collaborative Fund , a New York-based venture fund, is a leading source of capital and strategic support for entrepreneurs, businesses, and protocols pushing the world forward.

Key Points: 
  • Collaborative Fund , a New York-based venture fund, is a leading source of capital and strategic support for entrepreneurs, businesses, and protocols pushing the world forward.
  • As part of the alliance, Collaborative Fund will provide $15 million to create a Laboratory for Sustainable Materials Research and Innovation at the Wyss Institute to support research into transformational technology with strong commercial potential.
  • Collaborative Fund has over a decade of experience investing in climate technology and recently launched a dedicated $200M climate fund, Collab SOS , to fuel a more sustainable economy across materials, ingredients, energy, and supply chains.
  • When it comes to climate change, there’s no time to waste,” said Sophie Bakalar, partner at Collaborative Fund.

Lifespin Announces Inaugural Membership in the Industrial Participant Program of the Wyss Diagnostics Accelerator at Harvard University

Retrieved on: 
Thursday, April 20, 2023

Lifespin GmbH, based in Regensburg with offices in Boston, Massachusetts, announced today that it is one of 24 inaugural members of the Wyss Institute for Biologically Inspired Engineering at Harvard University’s Diagnostics Accelerator ( Wyss DxA ) Industrial Participant Program (IPP).

Key Points: 
  • Lifespin GmbH, based in Regensburg with offices in Boston, Massachusetts, announced today that it is one of 24 inaugural members of the Wyss Institute for Biologically Inspired Engineering at Harvard University’s Diagnostics Accelerator ( Wyss DxA ) Industrial Participant Program (IPP).
  • Originally formed in 2021 as a pilot program, the IPP recently has transitioned from its pilot phase into an official program within the Harvard system, and consolidated its base of initial industrial partners, including Lifespin.
  • “The mission of the Wyss DxA is to get transformative diagnostic tests to market and reduce disease burden for patients with major unmet needs.
  • Lifespin ( www.lifespin.health ) is a deep data company that seeks to detect distinct deviations in the human metabolism caused by diseases.

Wyss Institute’s Lab-on-a-Molecule Drug Discovery Project Receives Funding from Northpond Labs

Retrieved on: 
Tuesday, April 4, 2023

This is the third Wyss project to which Northpond Labs has provided funding and in-kind support to ensure a pathway toward rapid technology commercialization.

Key Points: 
  • This is the third Wyss project to which Northpond Labs has provided funding and in-kind support to ensure a pathway toward rapid technology commercialization.
  • In 2020, the Wyss Institute, Northpond Labs and other collaborating institutions launched the Laboratory for Bioengineering Research and Innovation at the Wyss Institute as part of a research collaboration.
  • In 2022, the Institute, in partnership with Northpond Labs, spun out EnPlusOne Biosciences, an RNA solutions company which started as a controlled enzymatic RNA synthesis project funded by Northpond Labs in 2020.
  • Because of its potential as a next-generation drug discovery technology, the Lab-on-a-Molecule project had already been selected by the Wyss Institute as one of its 2022 Validation Projects .

New Survey Finds Consumers Still Disposing Non-Flushable Items Down the Toilet, Sparking Increase in Consumer Education Efforts

Retrieved on: 
Wednesday, April 5, 2023

SEATTLE, April 5, 2023 /PRNewswire-PRWeb/ -- Today, the Responsible Flushing Alliance (RFA) released insights and an infographic from a survey of California consumers measuring general awareness of the "Do Not Flush" symbol. It also measured Californians' understanding of what common household products are not flushable.

Key Points: 
  • SEATTLE, April 5, 2023 /PRNewswire-PRWeb/ -- Today, the Responsible Flushing Alliance (RFA) released insights and an infographic from a survey of California consumers measuring general awareness of the "Do Not Flush" symbol.
  • This is a 6-point increase (from 69% to 75%) in awareness from the baseline survey conducted in the Fall of 2021.
  • "We know consumer education works; we've seen that in our 2022 pilot campaign," Wyss said.
  • If your organization is interested in helping RFA spread its consumer education to more consumers, please visit our website at flushsmartcalifornia.org or find us @FlushSmart on Facebook, Twitter, YouTube, and LinkedIn.

EnPlusOne Biosciences Expands Scientific Advisory Board

Retrieved on: 
Wednesday, February 8, 2023

EnPlusOne Biosciences, Inc. , a biotechnology company harnessing the power of enzymes to synthesize RNA oligonucleotides, today announced that Jonathan K. Watts, Ph.D., Professor, RNA Therapeutics Institute and Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Chan Medical School, has been appointed to the company’s Scientific Advisory Board.

Key Points: 
  • EnPlusOne Biosciences, Inc. , a biotechnology company harnessing the power of enzymes to synthesize RNA oligonucleotides, today announced that Jonathan K. Watts, Ph.D., Professor, RNA Therapeutics Institute and Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Chan Medical School, has been appointed to the company’s Scientific Advisory Board.
  • Dr. Watts, who was also a member of the Board of Directors of the Oligonucleotide Therapeutics Society (OTS) from 2015 to 2021, is a highly regarded scientific investigator in the oligonucleotide field.
  • Daniel Wiegand, MSChE, CEO of EnPlusOne said, “We are delighted to attract an experienced, respected researcher like Jon to our Scientific Advisory Board.
  • He serves on the Editorial Boards of Nucleic Acid Therapeutics and Nucleic Acids Research in addition to the Scientific Advisory Council of the OTS.

EnPlusOne Biosciences Launches Enzymatic RNA Synthesis Platform with $12 Million in Seed Financing

Retrieved on: 
Friday, September 30, 2022

EnPlusOne Biosciences, Inc. , a biotechnology company harnessing the power of enzymes to synthesize RNA oligonucleotides, today formally launched with $12 million in seed financing.

Key Points: 
  • EnPlusOne Biosciences, Inc. , a biotechnology company harnessing the power of enzymes to synthesize RNA oligonucleotides, today formally launched with $12 million in seed financing.
  • The financing will support continued development and scaling of the companys proprietary ezRNA synthesis platform in line with the companys mission to enable next-generation solutions for emerging RNA therapeutics.
  • EnPlusOne is pioneering an enzymatic-based RNA synthesis platform to address systemic issues inherent to existing chemical synthesis methods.
  • In addition to direct RNA synthesis, EnPlusOne's ezRNA platform supports a vast array of RNA solution applications.